NCT03574545View on ClinicalTrials.gov

Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2024

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

ianalumab

Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)

Trial Locations (2)

10117

Novartis Investigative Site, Berlin

11941

Novartis Investigative Site, Amman

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT03574545 - Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter